USD Pfizer Express – available on secondary market

USD Pfizer Express – available on secondary market

Reach Your Target by Express – opportunity for yield between 10% and 50% with a maximum term of 5 years

Advertisement

The USDPfizer Express certificate combines the opportunity to generate an attractive yield with the possibility for an early redemption. The share of Pfizer Inc. serves as underlying for the investment product without capital protection. The Express Certificate offers an attractive profit opportunity for those investors who expect the Pfizer share to quote at or above its current level within the forthcoming five years.

Term:

The certificate has a minimum term of 1year and a maximum term of 5 years. If the closing price of the Pfizer share quotes at or above its redemption level (equal to the share’s closing price at the initial valuation date) at one of the annual valuation dates, (early) redemption is effected according to the predefined redemption price.

Yield opportunity:

If the share quotes below the starting value at the annual valuation date, the term extends by another year (up to a maximum term of five years). At the same time, the potential annual termination price rises by 10% of the nominal value annually (up to a maximum of 150%).

Safety mechanism:

If the certificate is not redeemed in the first four years and provided that the underlying quotes below the termination level at the fifth and final valuation date, an additional safety mechanism applies: in case the closing price of the Pfizer Inc. share quotes above the barrier of 60% at the final valuation date, redemption is effected at 100% of the nominal value. This means investors do not generate profit and the nominal value of USD 1,000 is redeemed.

If the barrier is touched or undercut at the final valuation date physical delivery applies. Then the investor gets the Pfizer Inc. shares in the amount predefined at the issue date (nominal value/strike). The difference to the integral number is paid out. In this case, the lower share price of the delivered shares may result in the loss of a major part of the capital.

Currency risk/opportunity: This certificate is not currency hedged. If the cash flows from the certificate (repayment) are later converted into another currency, additional risks as well as opportunities arise from possible fluctuations of the currency price in relation to the nominal value.

Further information as well as the Key Information Document please find on the product page.

Express Certificates – explained shortly:

Please adjust your cookie settings to allow YouTube videos or start the video here: External link to the video on YouTube

For any additional information you may require do not hesitate to contact us on +43 1 515 20-484.

The Team Structured Products of Raiffeisen Centrobank

 

Key facts:
  • Name: USD Pfizer Express Sustainable certificate
  • ISIN: AT0000A2MMK5
  • Initial valuation date: Feb 16, 2021
  • Term: min. 2 years, max. 2 years
  • Listing: Stuttgart
Disclaimer
This is advertising. This non-binding information does not constitute advice, recommendation or invitation to conclude a transaction. The presentation is of a generic nature, does not take into account the personal circumstances of potential investors and therefore cannot replace individual investor and investment-oriented advice and risk disclosure. This advertisement has not been prepared in compliance with the legal provisions promoting the independence of investment research and is not subject to the ban on trading following the dissemination of investment research. A base prospectus (including any supplements) that complies with the Austrian Capital Market Act and has been approved by the competent authorities (CSSF, FMA) is available on the website of Raiffeisen Bank International AG (raiffeisencertificates.com/en/securities-prospectus/). The approval of the base prospectus by the competent authorities is not to be understood as an endorsement by the competent authorities of the financial instruments described herein. We recommend reading the prospectus before making an investment decision. Important additional information on the products described (in particular their opportunities and risks) can be found on the website of Raiffeisen Bank International AG at raiffeisencertificates.com/en/; in particular, the approved base prospectus (including any supplements) can be found at (raiffeisencertificates.com/en/securities-prospectus/) and under "Customer Information and Regulatory Issues" at raiffeisencertificates.com/en/customer-information/. Regulatory authorities: Austrian Financial Market Authority (FMA), European Central Bank (ECB). Imprint according to Austrian media law: Media owner and producer is Raiffeisen Bank International AG, Am Stadtpark 9, 1030 Vienna/Austria.